Compare Stocks: VIRI, MIST, NMRA, and VTVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIST Milestone Pharmaceuticals	$0.52 -20.6%	$0.80	$0.50 ▼ $3.06	$81.57M	1.07	1.23 million shs	4.14 million shs
NMRA Neumora Therapeutics	$0.43 -0.9%	$0.60	$0.32 ▼ $3.65	$81.36M	3.12	1.72 million shs	554,776 shs
VIRI Virios Therapeutics	$1.11 -0.9%	$1.43	$0.13 ▼ $1.04	$21.38M	1.58	1.05 million shs	74,653 shs
VTVT vTv Therapeutics	$19.69 -4.8%	$28.04	$19.04 ▼ $44.00	$81.50M	0.28	21,877 shs	17,404 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIST Milestone Pharmaceuticals	-20.63%	-31.83%	-34.00%	-52.73%	-73.06%
NMRA Neumora Therapeutics	-0.95%	-14.78%	+20.99%	-73.19%	-85.00%
VIRI Virios Therapeutics	-8.94%	+7.69%	-13.85%	-47.91%	-80.14%
VTVT vTv Therapeutics	-4.83%	-6.37%	-28.45%	-34.63%	-36.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIST Milestone Pharmaceuticals	$0.52 -20.6%	$0.80	$0.50 ▼ $3.06	$81.57M	1.07	1.23 million shs	4.14 million shs
NMRA Neumora Therapeutics	$0.43 -0.9%	$0.60	$0.32 ▼ $3.65	$81.36M	3.12	1.72 million shs	554,776 shs
VIRI Virios Therapeutics	$1.11 -0.9%	$1.43	$0.13 ▼ $1.04	$21.38M	1.58	1.05 million shs	74,653 shs
VTVT vTv Therapeutics	$19.69 -4.8%	$28.04	$19.04 ▼ $44.00	$81.50M	0.28	21,877 shs	17,404 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIST Milestone Pharmaceuticals	-20.63%	-31.83%	-34.00%	-52.73%	-73.06%
NMRA Neumora Therapeutics	-0.95%	-14.78%	+20.99%	-73.19%	-85.00%
VIRI Virios Therapeutics	-8.94%	+7.69%	-13.85%	-47.91%	-80.14%
VTVT vTv Therapeutics	-4.83%	-6.37%	-28.45%	-34.63%	-36.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MIST Milestone Pharmaceuticals	2.71	Moderate Buy	$6.40	1,130.77% Upside
NMRA Neumora Therapeutics	2.78	Moderate Buy	$6.57	1,432.16% Upside
VIRI Virios Therapeutics	0.00	N/A	N/A	N/A
VTVT vTv Therapeutics	2.78	Moderate Buy	$55.83	183.56% Upside

Current Analyst Ratings Breakdown

Latest VIRI, MIST, NMRA, and VTVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/4/2026	VTVT vTv Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	VTVT vTv Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$57.00
10/12/2026	MIST Milestone Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/25/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/3/2026	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/2/2026	VTVT vTv Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
8/20/2026	MIST Milestone Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$3.00
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 11/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MIST Milestone Pharmaceuticals	$1.55M	41.77	N/A	N/A	$0.39 per share	1.33
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A
VTVT vTv Therapeutics	$1.02M	76.06	N/A	N/A	$17.69 per share	1.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MIST Milestone Pharmaceuticals	-$63.06M	-$0.69	N/A	N/A	N/A	N/A	-288.33%	-58.27%	N/A
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A
VTVT vTv Therapeutics	-$26.97M	-$0.92	N/A	N/A	N/A	N/A	-10.15%	-8.65%	N/A

Latest VIRI, MIST, NMRA, and VTVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	MIST Milestone Pharmaceuticals	-$0.2157	-$0.18	+$0.0357	-$0.18	$1.00 million	$2.96 million
11/5/2026	Q3 2026	VTVT vTv Therapeutics	-$1.09	-$0.94	+$0.15	-$0.94	$0.33 million	N/A
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MIST Milestone Pharmaceuticals	3.25	8.13	7.92
NMRA Neumora Therapeutics	1.19	4.50	4.50
VIRI Virios Therapeutics	N/A	7.27	7.27
VTVT vTv Therapeutics	N/A	11.19	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MIST Milestone Pharmaceuticals	86.18%
NMRA Neumora Therapeutics	47.65%
VIRI Virios Therapeutics	9.05%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
MIST Milestone Pharmaceuticals	5.03%
NMRA Neumora Therapeutics	26.94%
VIRI Virios Therapeutics	12.20%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MIST Milestone Pharmaceuticals	38	124.50 million	118.24 million	Optionable
NMRA Neumora Therapeutics	63	187.90 million	137.28 million	Optionable
VIRI Virios Therapeutics	5	19.26 million	16.91 million	No Data
VTVT vTv Therapeutics	26	3.94 million	3.70 million	Not Optionable

VIRI, MIST, NMRA, and VTVT Headlines

Recent News About These Companies

Comparing vTv Therapeutics (VTVT) and Its Rivals

November 7, 2026 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Stock Bumped Up to "Hold" by Wall Street Zen

November 7, 2026 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

November 7, 2026 | marketbeat.com

vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 5, 2026 | finance.yahoo.com

vTv Therapeutics (VTVT) Projected to Post Earnings on Thursday

November 4, 2026 | americanbankingnews.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Price Target of $55.83

November 1, 2026 | marketbeat.com

vTv Therapeutics (VTVT) Expected to Release Quarterly Earnings on Thursday

October 29, 2026 | marketbeat.com

vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL ...

October 27, 2026 | markets.businessinsider.com

vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems

October 27, 2026 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Bumped Down to Sell by Wall Street Zen

October 24, 2026 | marketbeat.com

vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript

October 20, 2026 | seekingalpha.com

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

October 20, 2026 | marketbeat.com

vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026

October 10, 2026 | markets.businessinsider.com

Millennium Management and Israel Englander Reveal 8.7% Stake in vTv Therapeutics

October 9, 2026 | kalkinemedia.comK

vTv Therapeutics stock jumps on FDA orphan drug status

October 8, 2026 | uk.finance.yahoo.com

Analysts Conflicted on These Healthcare Names: vTv Therapeutics (VTVT) and CSL (OtherCMXHF)

October 8, 2026 | theglobeandmail.com

VTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell Disease

October 8, 2026 | rttnews.com

FDA grants orphan drug status to vTv Therapeutics' sickle cell drug

October 8, 2026 | streetinsider.com

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

October 7, 2026 | globenewswire.com

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

October 6, 2026 | globenewswire.com

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

October 5, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VIRI, MIST, NMRA, and VTVT Company Descriptions

Milestone Pharmaceuticals NASDAQ:MIST

$0.52 -0.14 (-20.63%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$0.51 -0.01 (-2.31%)

As of 11/13/2026 07:58 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Neumora Therapeutics NASDAQ:NMRA

$0.43 0.00 (-0.95%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$0.45 +0.02 (+4.92%)

As of 11/13/2026 07:51 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Virios Therapeutics NASDAQ:VIRI

$1.11 -0.01 (-0.89%)

As of 11/13/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

vTv Therapeutics NASDAQ:VTVT

$19.69 -1.00 (-4.83%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$19.61 -0.08 (-0.41%)

As of 11/13/2026 04:10 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIRI, MIST, NMRA, and VTVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIRI, MIST, NMRA, and VTVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIRI, MIST, NMRA, and VTVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIRI, MIST, NMRA, and VTVT Company Descriptions

Milestone Pharmaceuticals NASDAQ:MIST

Neumora Therapeutics NASDAQ:NMRA

Virios Therapeutics NASDAQ:VIRI

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIRI, MIST, NMRA, and VTVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIRI, MIST, NMRA, and VTVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIRI, MIST, NMRA, and VTVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIRI, MIST, NMRA, and VTVT Company Descriptions

Milestone Pharmaceuticals NASDAQ:MIST

Neumora Therapeutics NASDAQ:NMRA

Virios Therapeutics NASDAQ:VIRI

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools